Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | NNVC |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5B | 21.2M |
| IPO Year | 1996 | 2008 |
| Metric | LNG | NNVC |
|---|---|---|
| Price | $238.89 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $294.87 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 998.8K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 69.93 | 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,976,000,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.21 | N/A |
| 52 Week Low | $186.20 | $0.85 |
| 52 Week High | $300.94 | $2.23 |
| Indicator | LNG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 48.85 |
| Support Level | $232.06 | $1.35 |
| Resistance Level | $240.94 | $1.52 |
| Average True Range (ATR) | 6.53 | 0.15 |
| MACD | 0.48 | -0.03 |
| Stochastic Oscillator | 54.59 | 14.00 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.